Purpose. Staphylococcus aureus is an opportunistic human pathogen that can cause serious infections in humans. A plethora of known and putative virulence factors are produced by staphylococci that collectively orchestrate pathogenesis. Ear protein (Escherichia coli ampicillin resistance) in S. aureus is an exoprotein in COL strain, predicted to be a superantigen, and speculated to play roles in antibiotic resistance and virulence. The goal of this study was to determine if expression of ear is modulated by single nucleotide polymorphisms in its promoter and coding sequences and whether this gene plays roles in antibiotic resistance and virulence.
INTRODUCTION
Staphylococcus aureus colonizes nearly one-third of the human population without producing any detectable disease, a remarkable feature that enhances its spread among the population and frequency of recurrent infections [1, 2] . However, S. aureus is also an opportunistic pathogen capable of causing a variety of human diseases ranging from mild skin infections to devastating destruction of any organ system to which it gains access. S. aureus infections are a source of serious morbidity and mortality in both hospital and community settings [3, 4] .
S. aureus produces a large number of virulence factors that promote bacterial colonization of human tissues and subsequently contributes to pathogenesis [5] . Until the mid1990s, infection with methicillin-resistant S. aureus (MRSA) remained a rare occurrence outside of the healthcare system. However, there has been an explosive rise in MRSA infections among those without prior healthcare exposure. This group referred to as community-associated MRSA (CA-MRSA) is epidemiologically different with respect to variances in genetic lineage and enhanced virulence potential and profile [6, 7] .
The ear gene (Escherichia coli ampicillin resistance) was first identified in S. aureus pathogenicity island (SaPI) 3 and subsequently found to be part of SaPI1, SaPI3, SaPI4 and SaPI5 [8, 9] . As part of the SaPI, ear is an accessory gene (i.e. unrelated to the SaPI life cycle) with a possible role in antibiotic resistance [9] . While its function is not studied, characteristics of this gene suggest that it could play an important function in S. aureus. Its position on SaPI and predicted protein sequence are conserved (~75 % identify at Downloaded from www.microbiologyresearch.org by IP: 54.70.40.11
On: Sun, 30 Dec 2018 03:51:43 the amino acid level). The Ear protein of SaPI3 from S. aureus COL strain was identified as 185 amino acids long, with a predicted molecular mass of 20.2 kDa. The ear gene is believed to be a superantigen-encoding gene occurring at the end of the Sa1 int phages [10, 11] . Shukla et al. [12] in an analysis of carriage S. aureus, clinical S. aureus, and CA-MRSA showed that CA-MRSA USA400 strains harbour higher percentages of ear genes than the nasal carriage and clinical MSSA groups. The ear located on genomic island, vSa3 has been suggested to be a putative S. aureus virulence gene [13] .
A BLAST search of the ear gene from MW2 identifies it to have a putative conserved domain belonging to the SA1633_like superfamily, an uncharacterized protein family conserved in staphylococci (specific hit, evalue=1.13e-51; cd15783) although some proteins in this family have been described as putative beta-lactamases. They are structurally similar to the C-terminal beta-grasp domains of staphylococcal and streptococcal superantigens. Despite being proposed as a virulence factor in CA-MRSA strain, MW2 [13] , the Ear protein of S. aureus remains poorly characterized. In a study of S. aureus infections among geriatric patients in a Spanish hospital, the ear gene was present in 35.5 % of bloodstream isolates of S. aureus and 96.8 % of wound isolates [14] . In addition, this exoprotein from MW2 and USA300 reacted to the sera of mice infected with these two CA-MRSA strains [15] . Novick and Subedi stated that several S. aureus strains carry the ear gene and it encodes a penicillin-binding protein homologue which determines penicillin resistance in Escherichia coli [9] . The aim of this study was to characterize the ear gene and its expression in carriage and clinical MSSA and MRSA isolates and its impact on the pathophysiology of a clinically significant and an epidemic CA-MRSA clone, USA300, since it was highly expressed in the USA300 type strain.
METHODS

S. aureus isolate selection
Strains were selected from our archived S. aureus biobank dating back to 1987. The strains represented belonged to the following four phenotypes: carriage MSSA, clinical MSSA, CA-MRSA, and nosocomial MRSA.
Strain characterization
Strains were characterized for their oxacillin susceptibility, multilocus sequence types, spa typing and agr typing by following the protocols described in detail in Shukla et al. [12] .
PCR and primer design for ear sequence analysis
In order to design a broad range of primers for the ear gene from a variety of S. aureus isolates, the ear gene of the following strains (genome-sequenced), MW2, COL, USA300 FPR3757, USA300 TCH1516, JH1, JH9, N315, Mu3 and Mu50 were used to design PCR and sequencing primers that could be used to amplify the gene from multiple S. aureus phenotypes used in the study. Subsequently, four primer sets were designed (Table 1) to amplify the 100 bp ear upstream and full coding regions.
Growth curves
A subset of isolates used in the study was grown for 4.5 h to late log phase in tryptic soy broth (TSB). To prepare the cultures, 250 µl of an overnight culture was used to inoculate 50 ml of TSB and grown at 37 C, 150 r.p.m.
RNA extraction and reverse transcriptase PCR (RT-PCR)
These methods have been described in detail in a previous publication [16] . The primers and probe sequences are described in Table 1 .
Relative quantification using the comparative C T (2 ÀDDC T ) method A comparative cycle threshold (2 ÀDDC T ) method was used to calculate the relative quantification of target genes based on 2
-(target gene C T -reference gene C T ) . The comparative cycle threshold (2 ÀDDC T ) method for calculating relative quantification provides reliable expression data of target genes compared to an internal control gene. This method operates strictly under the assumption that the PCR efficiency is mathematically perfect, and does not correct for inefficiencies.
DNA extraction, ear amplification and sequencing Genomic DNA was extracted from lysostaphin-treated S. aureus cells using the QIAGEN QIAamp DNA Mini Kit. The ear upstream and coding sequences were amplified and the amplicons were sequenced using an ABI3100 sequencer (Applied Biosystems). The nucleotide sequence data was analysed with the DNASTAR (Lasergene, Version 7.2.1) and then submitted to the NCBI BLAST database for sequence confirmation. The sequences were submitted to GenBank and the assigned accession numbers are MF466181-MF466209. Sequence comparisons, amino acid alignments and phylogenetic analyses were performed in Geneious (Geneious version 9.1.7 (www.geneious.com) [17] . Protein homology and modelling was performed in Phyre2 (the Phyre2 web portal for protein modelling, prediction and analysis) [18] . The amino acid sequence alignment identity across positions was compared by t-test using Excel.
Real-time PCR assay and expression of ear in various S. aureus strains Expression of the ear gene was determined using a real-time RT-PCR assay. Primers were designed using the first 110 bp of the ear coding region from all nine S. aureus strains for gene expression analysis. A Taqman probe was also designed and tagged with a 5¢ reporter dye (FAM) and a 3¢ quencher from the expected amplicon. The specificity of all primers and probes were confirmed by BLAST analysis against published S. aureus genome sequences. For gene expression analysis, total RNA was extracted from 1.5 ml of stationary phase culture and the contaminating genomic DNA was eliminated using TURBO DNA-free kit (Applied Biosystems). Initially, cDNA was prepared using the HighCapacity cDNA Reverse Transcription Kit (Applied Biosystems). The level of ear transcript was then determined using this cDNA as template, ear-specific primers and probes (Table 1) . Final primer and probe concentrations were 900 and 250 nM, respectively, and all reactions were carried out in duplicate. Relative ear expression was determined after normalization to gmk mRNA.
Level of ear expression in other strains in reference to its expression in S. aureus strain COL was also calculated using the formula 2 ÀDDC T as described [19] .
JE2 (plasmid free USA300) wild-type and ear mutant strains The wild-type JE2 and its derivative ear mutant (NE375) were obtained from the Nebraska Transposon Mutant Library [20] . The mutant was verified by PCR using appropriate primers. For complementation, a 958 bp DNA fragment was PCR-amplified using a pair of primers (forward: 5¢-GGATCCGTCAGCCCGAAGGCTAACTTACG-3¢; and reverse: 5¢-AAGCTTCTGAGAAACGCCCTGTGTTG-3¢) using genomic DNA from S. aureus strain USA300 as the template and cloned into the cloning vector pCU1 [21] . The resulting construct was subsequently introduced into the ear mutant.
Growth kinetics of the wild-type S. aureus and its isogenic ear mutant Mid-exponential phase cultures (OD 600 =0.6) were diluted 50-fold in a culture flask (Wheaton) containing 50 ml fresh TSB with a flask-to-medium volume ratio of 6 : 1 and growth was measured spectrophotometrically every 30 min. For growth in the presence of ampicillin, the cultures were pre-grown to OD 600 =0.3 and then ampicillin was added at 40 µg ml
À1
.
Determination of MIC
Automated susceptibility testing for JE2, JE2 : Dear, JE2 :
Dear+complemented plasmid was performed for ampicillin, ceftriaxone, ceftaroline, chloramphenicol, ciprofloxacin, clindamycin, daptomycin, erythromycin, gentamycin, levofloxacin, linezolid, oxacillin+2 % Nacl, penicillin, rifampin, tetracycline, trimethoprim and vancomycin using Thermo Scientific Sensititre GPALL3F panels (Oakwood Village, OH, USA) in accordance with the manufacturer's specifications. Panels were read using the Thermo Scientific Sensititre ARIS system (automated read). Results were interpreted using the Sensititre SWIN Software system applying CLSI breakpoints.
Antibiotic MIC for bacitracin, D-cycloserine and minocycline was determined by standard broth microdilution methodology (per CLSI standards) using Mueller-Hinton broth (MHB) and 96-well U-bottom plates as described previously [18] .
Survival of wild-type JE2 and ear mutants in a murine systemic infection model All animal work was reviewed and approved by the IACUC of the AT Still University. Wild-type JE2 and ear mutants were mixed together and then tested in a murine systemic infection model to determine if the mutation had an effect on in vivo survival of S. aureus. A 0.25 ml mixture of the wild-type and ear mutant cells (~1Â10 7 c.f.u., approximately 50 : 50 ratio of the wild-type JE2 and the ear mutant) was injected into the peritoneal cavity of Swiss white Hla (ICR) CVF female mice (16-20 g) (Hilltop Lab Animals) and the fraction of mutants surviving in the spleen and liver of infected mice was enumerated relative to wild-type JE2 as described previously [22] .
Association between agr types and ear expression A t-test was used to test the statistical differences of expression ratios between two agr groups which include agr type I compared with agr type III, agr type I compared with agr type IV and agr type III compared with agr type IV. The limitation of this analysis was the sample sizes of each group which were 10, 5 and 4 for agr types I, III and IV, respectively.
RESULTS
S. aureus ear characterization
The size of the ear gene was variable and ranged from 555 bp (MW2 and USA300 strains) to 561 bp (carriage isolates). The ear coding and 100 bp upstream region of 28 S. aureus isolates were analysed and based on the presence of single nucleotide polymorphisms and sequence similarities, they could be placed into seven clusters, consisting of three main groups (groups 1-3) represented by wellcharacterized strains such as USA300-like (n=5), MW2-like (n=5) and COL-like (n=7), respectively, and four unique groups called unique groups 1-4. The four unique groups were represented by 11 strains as in unique grp 1 (n=2), unique grp 2 (n=3), unique grp 3 (n=4) and unique grp 4 (n=2). Sequence similarity was based on the Tamura Nei genetic distance neighbour-joining tree (Fig. 1) .
The Ear protein size ranged from 184 amino acids (MW2-and USA300-like strains), 185 amino acids (COL), to 186 amino acids for N315. Comparison at the amino acid sequence level with respect to the MW2 strain showed regions of the protein where most of the differences are located (Fig. 2a) . Using Phyre [12] to look for sequence homology between Ear and any protein for which secondary structure was determined, we noted that the Ear sequence of each of the 29 strains matched with 100 % confidence to c2mqba [23] , probably a beta lactamase from S. aureus Mu50. A secondary structure was generated by Phyre2 and is shown in Fig. 2b with the amino acid sequence corresponding to the various secondary structure elements shown in Fig. 3 . The 100 % confidence represented the probability (from 0 to 100) that the match between the Ear protein sequence and the template match found by the heuristic search algorithm was a true homology [18] . Table 2 shows that the amino acid positions involved in a predicted secondary structure of Ear had a higher percentage identity compared to amino acid positions that were not involved in a predicted protein secondary structure (P<0.005). Therefore, while there are amino acid substitutions across Ear, one could argue that the core structure of Ear is conserved. Expression analyses of ear in different S. aureus isolates The ear expression was measured from 20 selected strains representing seven clonal complexes, all four agr (accessory gene regulator) types, and a number of spa types ( Table 3 ). The expression of ear showed significant variation from isolate to isolate with some strains showing no expression to others (SA61S, USA300, SA85S and SA116S) showing 25-fold more expression than gmk (Fig. 4a) . Again, with respect to the COL strain the ear expression was 25-to 37-fold higher (Fig. 4b) . Interestingly, agr 1 type isolates had significantly higher ear expression compared to either agr type III (P-value =<0.05) and agr IV (P-value =<0.05, Fig. 5 ). However, no correlation was observed between a specific group of mutations in the upstream region or in the coding sequence and the level of ear expression. In addition, CA-MRSA strains, which are more virulent and hypothesized to possibly express higher levels of ear than MSSA or carriage isolates, did not consistently show elevated levels of expression. Since USA300 was one of the strains that showed 27.5-fold higher expression, we wanted to see if the ear mutant in Fig. 3 . Secondary structure and disorder prediction for the amino acid sequence of the MW2 Ear protein as reported by Phyre2, a web portal for protein modelling, prediction and analysis. The amino acid sequences of the 28 ear genes described in the paper bore sufficient similarity to map to the same predicted secondary structure elements as shown here. a USA300 genetic background has any effect on growth kinetics and virulence in a mouse model.
Potential roles of Ear in S. aureus virulence
In growth kinetics experiments, there was no apparent growth difference between the wild-type JE2 and its derivative ear mutant (Fig. 6a) . After complementation in trans, the ear mutant still showed a growth rate similar to the wild-type or the ear mutant without complementation. As Ear is predicted to be associated with resistance to the antimicrobial agent, ampicillin, the growth of the JE2 wild-type, its isogenic ear mutant, and the complemented strains were also investigated in TSB with ampicillin. In the presence of ampicillin as well, these three strains showed a similar growth rate (Fig. 6b) . In antibiotic MIC determination experiments, the ear mutant displayed a twofold reduction in ampicillin resistance but resistance to several other antibiotics was identical between the wild-type, JE2 and its derivative ear mutant ( Table 4 ). The ear mutant and the complemented strain were resistant to erythromycin due to the insertion of a transposon carrying erythromycin resistance gene in the ear coding region. The complemented strain is resistant to chloramphenicol due to the presence of plasmid pCU1 containing the ear gene (Table 4) .
Survival of wild-type JE2 and the ear mutant in mice To determine the significance of Ear protein in the virulence of S. aureus, mice were injected with a~50 : 50 mixture of wild-type JE2 and the ear mutant. These mice were sacrificed at 8 and 24 h after injection. The data suggests that the ratio of the wild-type JE2 and the ear mutant remained close to 50 : 50 in the liver and spleen tissues of the infected mice, both at 8 and 24 h, respectively (Fig. 7) . The data suggests that lack of Ear confers no significant disadvantage to the survival of S. aureus cells.
DISCUSSION
Staphylococcal exotoxins contribute significantly to its pathogenicity [24, 25] . S. aureus ear, an exoprotein gene was first identified on SaPI 3 [8] and subsequently in MW2 strain is located on a unique genomic island containing two additional virulence genes, sec4 and sel2 [13] . In addition, ear has been identified in other sequenced CA-MRSA and nosocomial-MRSA strains including USA300 and COL [9, 26] . Within these strains also, ear is located on a mobile genetic element with two or more superantigen toxins. Ear is known to be produced by S. aureus during infection in vivo with detectable titre in sera from infected animals as opposed to sera from uninfected animal [15] .
In order to determine the virulence potential of Ear, expression of S. aureus ear was investigated in a variety of genetic backgrounds of clinical, carriage, MRSA and MSSA strains. Higher expression was significantly associated with agr type I isolates. Variability in ear expression levels could not be linked to a specific mutation(s) in upstream or coding sequences (data not shown). Since USA300 strains were among isolates that had shown higher ear expression, we speculated that a higher ear expression could contribute to its virulence.
A study that explored global gene expression levels in a USA300 strain in human blood, serum and TSB, noted that the ear expression levels were elevated in human blood from twofold at 30 min of growth to four-fivefold at 120 min when compared to its expression in TSB [10] . However, when grown in heparinized human serum, ear exhibited only a one-twofold increase in expression whereas its expression was repressed three-fourfold in S. aureus cultures grown in TSB. It was speculated that the significantly enhanced expression of ear in blood, but not in serum, could be associated with host cells present in blood and the absence of soluble molecules that are known to be present in plasma and whole blood.
The S. aureus strain JE2 is a derivative of strain USA300 that has been cured of the two plasmids [20] . Our investigations utilizing an isogenic ear mutant of USA300, however, showed no apparent defect in the in vitro growth or in vivo survival in a mouse model compared to its isogeneic wildtype strain. Lack of an apparent direct impact in the pathophysiology in a USA300 strain suggests that Ear could only be a minor factor contributing to the organism's increase in pathogenesis. In the absence of Ear protein, other S. aureus exoproteins and toxins might be sufficient for the virulence potential of S. aureus. Variability in the expression of ear was not completely surprising as it is not uncommon for a major S. aureus toxin to be expressed and regulated differentially in different clinically virulent strains. Said-Salim et al. have shown differential distribution and expression of a significant CA-MRSA virulence gene, lukF in different CA-MRSA genotypes [27] . Similarly, it has been shown that the two superantigen encoding genes ssl5 and ssl8 are not only differently expressed but also differently regulated in different genotypes of S. aureus strains [16, 28] .
In summary, although the ear gene is present in multiple genetic backgrounds, it is in higher percentages in clinical isolates including CA-MRSA strains [12] , and expressed as an exoprotein, lack of this protein in an ear-mutated strain has no apparent effect on S. aureus pathophysiology in a USA300 genetic background. Future experiments would include investigating ampicillin and penicillin MICs in MSSA isolates with variable ear expression in addition to determining if ear expression is controlled by other global regulatory systems in S. aureus, which may shed additional clues to its enhanced expression in blood but not in serum. 
